DE69227918T2 - VERWENDUNG EINES CDw52-SPEZIFISCHEN ANTIKÖRPERS ZUR BEHANDLUNG VON DURCH T-ZELLEN VERMITTELTEN GELENKENTZÜNDUNGEN - Google Patents

VERWENDUNG EINES CDw52-SPEZIFISCHEN ANTIKÖRPERS ZUR BEHANDLUNG VON DURCH T-ZELLEN VERMITTELTEN GELENKENTZÜNDUNGEN

Info

Publication number
DE69227918T2
DE69227918T2 DE69227918T DE69227918T DE69227918T2 DE 69227918 T2 DE69227918 T2 DE 69227918T2 DE 69227918 T DE69227918 T DE 69227918T DE 69227918 T DE69227918 T DE 69227918T DE 69227918 T2 DE69227918 T2 DE 69227918T2
Authority
DE
Germany
Prior art keywords
treatment
cdw52
ignitions
mediated
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69227918T
Other languages
English (en)
Other versions
DE69227918D1 (de
Inventor
Herman Waldmann
Geoffrey Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215749A external-priority patent/GB9215749D0/en
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of DE69227918D1 publication Critical patent/DE69227918D1/de
Application granted granted Critical
Publication of DE69227918T2 publication Critical patent/DE69227918T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69227918T 1991-10-15 1992-10-14 VERWENDUNG EINES CDw52-SPEZIFISCHEN ANTIKÖRPERS ZUR BEHANDLUNG VON DURCH T-ZELLEN VERMITTELTEN GELENKENTZÜNDUNGEN Expired - Lifetime DE69227918T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77559891A 1991-10-15 1991-10-15
GB929215749A GB9215749D0 (en) 1992-07-24 1992-07-24 Medicaments
PCT/GB1992/001884 WO1993007899A1 (en) 1991-10-15 1992-10-14 CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS

Publications (2)

Publication Number Publication Date
DE69227918D1 DE69227918D1 (de) 1999-01-28
DE69227918T2 true DE69227918T2 (de) 1999-05-12

Family

ID=26301317

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227918T Expired - Lifetime DE69227918T2 (de) 1991-10-15 1992-10-14 VERWENDUNG EINES CDw52-SPEZIFISCHEN ANTIKÖRPERS ZUR BEHANDLUNG VON DURCH T-ZELLEN VERMITTELTEN GELENKENTZÜNDUNGEN

Country Status (12)

Country Link
EP (1) EP0610447B1 (de)
JP (1) JP3535155B2 (de)
KR (1) KR100264218B1 (de)
AT (1) ATE174515T1 (de)
AU (1) AU671807B2 (de)
CA (1) CA2120911A1 (de)
DE (1) DE69227918T2 (de)
DK (1) DK0610447T3 (de)
ES (1) ES2125977T3 (de)
IL (1) IL103418A (de)
MY (1) MY115415A (de)
WO (1) WO1993007899A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618989B2 (en) * 1988-02-12 1992-01-16 British Technology Group Limited Improvements in or relating to antibodies
JPH05502586A (ja) * 1989-12-27 1993-05-13 セントカー・インコーポレーテツド Ｃｄ４受容体に対するキメラ免疫グロブリン
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin

Also Published As

Publication number Publication date
MY115415A (en) 2003-06-30
DE69227918D1 (de) 1999-01-28
WO1993007899A1 (en) 1993-04-29
JP3535155B2 (ja) 2004-06-07
KR100264218B1 (ko) 2000-08-16
DK0610447T3 (da) 1999-08-23
AU2698592A (en) 1993-05-21
EP0610447A1 (de) 1994-08-17
IL103418A0 (en) 1993-03-15
IL103418A (en) 1997-11-20
JPH07500330A (ja) 1995-01-12
CA2120911A1 (en) 1993-04-29
EP0610447B1 (de) 1998-12-16
ATE174515T1 (de) 1999-01-15
ES2125977T3 (es) 1999-03-16
AU671807B2 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
DK0616537T3 (da) CDw52-specifikt antistof til behandling af dissemineret sclerose
DE69329621D1 (de) MONOKLONALE ANTIKöRPER GEGEN DEFINIIERTE REGIONEN DES T-ZELL-ANTIGENREZEPTORS
LU92048I2 (fr) Tocilizumab
GB2294267A (en) Antibody fragments in therapy
DE10199051I2 (de) Modifizierte Antik¦rper.
EA200200503A1 (ru) Способ лечения ревматоидного артрита
ATE233814T1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
DE69737292D1 (de) Peptid abgeleitet von einem antigen das von antikörpern aus patienten mit rheumatoider arthritis erkannt wird, antikörper gegen dieses peptid und ein verfahren zum nachweis von autoimmunantikörpern
DE69227918T2 (de) VERWENDUNG EINES CDw52-SPEZIFISCHEN ANTIKÖRPERS ZUR BEHANDLUNG VON DURCH T-ZELLEN VERMITTELTEN GELENKENTZÜNDUNGEN
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
FI930106A (fi) Cenp-b-epitop
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
DE69329109T2 (de) Nachweisverfahren für adrenale autoantikörper
EA200101271A1 (ru) Блокирующее моноклональное антитело к vla-1 и его применение для лечения воспалительных заболеваний
ATE169332T1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast
DE69333683D1 (de) Antikörper-testbesteck zur bestimmung von amylin
ATE130856T1 (de) Menschlicher monoklonaler antikörper gegen candida.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 610447

Country of ref document: EP